Anti-tumor Antibody Isotype Response Can Be Modified with Locally Administered Immunoadjuvants

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2022 Nov 23

PMID 36417163

Authors

Adam A Walters

Abrar Ali

Julie Tzu-Wen Wang

Khuloud T Al-Jamal

Affiliations

Soon will be listed here.

Abstract

In situ vaccination with immunostimulatory compounds is a demonstrated means to treat tumors preclinically. While these therapeutic effects have been attributed to the actions of T cells or innate immune activation, characterisation of the humoral immune response is seldom performed. This study aims to identify whether the injection of immunoadjuvants, Addavax (Adda) and cytosine-phosphorothioate-guanine oligodeoxynucleotide (CpG), intratumorally can influence the antibody response. Specifically, whether intratumoral injection of immunoadjuvants can alter the tumor-specific antibody target, titre and isotype. Following this, the study aimed to investigate whether serum obtained from in situ vaccinated mice could neutralise circulating tumor cells. Serum was obtained from mice bearing B16F10-OVA-Luc-GFP tumors treated with immunoadjuvants. Antibody targets' titre and isotype were assessed by indirect ELISA. The ability of serum to neutralise circulating cancer cells was evaluated in a B16F10 pseudo-metastatic model. It was observed that tumor-bearing mice mount a specific anti-tumor antibody response. Antibody titre and target were unaffected by in situ vaccination with immunoadjuvants; however, a higher amount of IgG2c was produced in mice receiving Adda plus CpG. Serum from in situ vaccinated mice was unable to neutralise circulating B16F10 cells. Thus, this study has demonstrated that anti-tumor antibody isotype may be modified using in situ vaccination; however, this alone is not sufficient to neutralise circulating cancer cells.

References

Ngamcherdtrakul W, Reda M, Nelson M, Wang R, Zaidan H, Bejan D . In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. Adv Mater. 2021; 33(31):e2100628. PMC: 8424660. DOI: 10.1002/adma.202100628. View

Yang M, Yan Y, Fang M, Wan M, Wu X, Zhang X . MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Int Immunopharmacol. 2012; 13(4):408-16. PMC: 7106219. DOI: 10.1016/j.intimp.2012.05.003. View

Visciano M, Tagliamonte M, Tornesello M, Buonaguro F, Buonaguro L . Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med. 2012; 10:4. PMC: 3311067. DOI: 10.1186/1479-5876-10-4. View

Guy T, Terry A, Bolton H, Hancock D, Shklovskaya E, Fazekas de St. Groth B . Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models. Cancer Immunol Immunother. 2016; 65(8):885-96. PMC: 11029718. DOI: 10.1007/s00262-016-1848-z. View

Leyland-Jones B . Trastuzumab: hopes and realities. Lancet Oncol. 2002; 3(3):137-44. DOI: 10.1016/s1470-2045(02)00676-9. View

Nimmerjahn F, Ravetch J . Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005; 310(5753):1510-2. DOI: 10.1126/science.1118948. View

Lorvik K, Hammarstrom C, Fauskanger M, Haabeth O, Zangani M, Haraldsen G . Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response. Cancer Res. 2016; 76(23):6864-6876. DOI: 10.1158/0008-5472.CAN-16-1219. View

Parratto N, Odebralski J, Kimura A . Poorly metastatic tumor cell variants as primary targets of syngeneic antibody responses against murine melanoma. Cancer Res. 1989; 49(14):3722-8. View

Hammerich L, Binder A, Brody J . In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Mol Oncol. 2015; 9(10):1966-81. PMC: 5528727. DOI: 10.1016/j.molonc.2015.10.016. View

10.

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

11.

Diaz-Zaragoza M, Hernandez-Avila R, Viedma-Rodriguez R, Arenas-Aranda D, Ostoa-Saloma P . Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review). Oncol Rep. 2015; 34(3):1106-14. PMC: 4530904. DOI: 10.3892/or.2015.4095. View

12.

Shirota Y, Shirota H, Klinman D . Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012; 188(4):1592-9. PMC: 3273593. DOI: 10.4049/jimmunol.1101304. View

13.

Newman J, Chesson C, Herzog N, Bommareddy P, Aspromonte S, Pepe R . Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A. 2020; 117(2):1119-1128. PMC: 6969546. DOI: 10.1073/pnas.1904022116. View

14.

Jegerlehner A, Maurer P, Bessa J, Hinton H, Kopf M, Bachmann M . TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. 2007; 178(4):2415-20. DOI: 10.4049/jimmunol.178.4.2415. View

15.

Ellyard J, Simson L, Parish C . Th2-mediated anti-tumour immunity: friend or foe?. Tissue Antigens. 2007; 70(1):1-11. DOI: 10.1111/j.1399-0039.2007.00869.x. View

16.

Hegde P, Chen D . Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011. View

17.

Gilbert A, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs D . Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One. 2011; 6(4):e19330. PMC: 3084832. DOI: 10.1371/journal.pone.0019330. View

18.

Inoue S, Leitner W, Golding B, Scott D . Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006; 66(15):7741-7. DOI: 10.1158/0008-5472.CAN-05-3766. View

19.

Xu Y, Ma S, Si X, Zhao J, Yu H, Ma L . Polyethyleneimine-CpG Nanocomplex as an In Situ Vaccine for Boosting Anticancer Immunity in Melanoma. Macromol Biosci. 2020; 21(2):e2000207. DOI: 10.1002/mabi.202000207. View

20.

Andreu P, Johansson M, Affara N, Pucci F, Tan T, Junankar S . FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010; 17(2):121-34. PMC: 3082507. DOI: 10.1016/j.ccr.2009.12.019. View